Currently, there are 80.74M common shares owned by the public and among those 79.59M shares have been available to trade.
The company’s stock has a 5-day price change of -3.19% and 8.18% over the past three months. IDXX shares are trading 21.32% year to date (YTD), with the 12-month market performance down to -3.25% lower. It has a 12-month low price of $356.14 and touched a high of $530.60 over the same period. IDXX has an average intraday trading volume of 862.66K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.69%, 13.37%, and 11.60% respectively.
Institutional ownership of Idexx Laboratories, Inc (NASDAQ: IDXX) shares accounts for 94.43% of the company’s 80.74M shares outstanding.
It has a market capitalization of $40.34B and a beta (3y monthly) value of 1.54. The stock’s trailing 12-month PE ratio is 46.35, while the earnings-per-share (ttm) stands at $10.82. The company has a PEG of 3.49 and a Quick Ratio of 0.76 with the debt-to-equity ratio at 0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.65% over the week and 2.31% over the month.
Earnings per share for the fiscal year are expected to increase by 13.90%, and 12.33% over the next financial year. EPS should shrink at an annualized rate of 13.28% over the next five years, compared to 16.90% over the past 5-year period.
Looking at the support for the IDXX, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on December 02, 2024, with the firm’s price target at $500. BTIG Research coverage for the Idexx Laboratories, Inc (IDXX) stock in a research note released on July 25, 2024 offered a Buy rating with a price target of $580. Piper Sandler was of a view on January 30, 2024 that the stock is Neutral, while Exane BNP Paribas gave the stock Outperform rating on December 07, 2023, issuing a price target of $602. Cleveland Research on their part issued Buy rating on December 04, 2023.
